CommercialDocumentationMedium impact
08.01.90b, Amivantamab-vmjw (Rybrevant®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.01.90b updates medical necessity criteria, medical coding guidelines, and general information for Amivantamab-vmjw (Rybrevant®), a specialty pharmaceutical agent. The billing team must review updated coverage requirements and coding guidance effective immediately to ensure compliant claims submission.
Action Required
By 2025-07-28: Billing and clinical teams must obtain and review the full policy text for Amivantamab-vmjw (Rybrevant®) at the provided URL to identify specific medical necessity criteria, updated coding requirements, and any prior authorization mandates. Update billing system rules, encounter templates, and provider documentation checklists accordingly. Ensure all claims for this drug include required medical necessity documentation. Contact the policy source (IBX) if clarification is needed on coding or coverage criteria. Failure to comply with updated medical necessity criteria may result in claim denials.